Jul 20, 2009 - A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that the U.S. FDA has accepted for review the New Drug Application (NDA) for APF530 for the potential treatment of chemotherapy-induced nausea and vomiting (CINV). APF530 is a long-acting formulation of granisetron that utilizes the Company's proprietary Biochronomer™ drug delivery system.
The details can be read here.
No comments:
Post a Comment